CoChat
Sign Up
Cited by 694Mesenchymal stem cell researchPeriodontal Regeneration and TreatmentsPluripotent Stem Cells Research

Shattering barriers toward clinically meaningful MSC therapies

Open access
Levy, Oren, Kuai, Rui, Siren, Erika M. J., Bhere, Deepak, Milton, Yuka, Nissar, Nabeel, De Biasio, Michael, Heinelt, Martina +8 more·2020·Science Advances
DOI 10.1126/sciadv.aba6884PMC PMC7439491
Open this paper in CoChat — free accountOpen PDF

Abstract

To realize the potential of MSCs, bioengineering is needed to boost potency and control heterogeneity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.aba6884

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MSCs vary in morphology, tri-lineage differentiation potential, proliferation rates, and immunomodulatory properties across different donors, tissue sources, subpopulations, and individual cells, referred to as heterogeneity.

    “Of note, MSCs vary in morphology, tri-lineage differentiation potential, proliferation rates, and immunomodulatory properties across different donors, tissue sources, subpopulations, and individual cells, referred to as heterogeneity [178, 308–310].”

    From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [309]

    The “Heterogeneity in the MSC product” section says MSCs are an inherently heterogeneous population whose therapeutic expression profiles vary with donor characteristics and tissue of origin. The manufacturing-challenges section mentions morphology, trilineage differentiation, and proliferative capacity as criteria or quality measures, but does not establish that these traits vary across donors, sources, subpopulations, or individual cells as claimed. Page numbers are unavailable in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Several parameters during cell preparation can influence the heterogeneity and therapeutic properties of MSC products, including isolation methods, culture conditions, cryopreservation, and thawing procedures.

    “In addition to cell sources, several parameters during cell preparation can influence the heterogeneity and therapeutic properties of MSC products, including isolation methods, culture conditions, cryopreservation, and thawing procedures [309].”

    From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [309]

  • Evidence indicates that the behavior of infused MSCs, including their pharmacokinetic and biological characteristics, can be influenced by the mode of administration such as the transplant site and the carrier materials/buffer used.

    “Evidence has indicated that the behavior of infused MSCs, including their pharmacokinetic and biological characteristics, can be influenced by the mode of administration such as the transplant site and the carrier materials/buffer used [84, 309].”

    From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [309]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 161

  1. [1]Friedenstein A. J., Gorskaja J. F., Kulagina N. N., Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp. Hematol. 4, 267– 274 (1976). 976387
  2. [2]Hass R., Kasper C., Bohm S., Jacobs R., Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun. Signal 9, 12 (2011). 21569606 PMC3117820
  3. [6]Riazifar M., Pone E. J., Lotvall J., Zhao W., Stem cell extracellular vesicles: Extended messages of regeneration. Annu. Rev. Pharmacol. Toxicol. 57, 125– 154 (2017). 27814025 PMC5360275
  4. [7]Galleu A., Riffo-Vasquez Y., Trento C., Lomas C., Dolcetti L., Cheung T. S., von Bonin M., Barbieri L., Halai K., Ward S., Weng L., Chakraverty R., Lombardi G., Watt F. M., Orchard K., Marks D. I., Apperley J., Bornhauser M., Walczak H., Bennett C., Dazzi F., Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci. Transl. Med. 9, eaam7828 (2017). 29141887
  5. [8]Prockop D. J., Concise review: Two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells 31, 2042– 2046 (2013). 23681848
  6. [9]Xia X., Chan K. F., Wong G. T. Y., Wang P., Liu L., Yeung B. P. M., Ng E. K. W., Lau J. Y. W., Chiu P. W. Y., Mesenchymal stem cells promote healing of nonsteroidal anti-inflammatory drug-related peptic ulcer through paracrine actions in pigs. Sci. Transl. Med. 11, eaat7455 (2019). 31666403
  7. [10]Gomzikova M. O., James V., Rizvanov A. A., Therapeutic application of mesenchymal stem cells derived extracellular vesicles for immunomodulation. Front. Immunol. 10, 2663 (2019). 31849929 PMC6889906
  8. [11]Zhao T., Sun F., Liu J., Ding T., She J., Mao F., Xu W., Qian H., Yan Y., Emerging role of mesenchymal stem cell-derived exosomes in regenerative medicine. Curr. Stem Cell Res. Ther. 14, 482– 494 (2019). 30819086
  9. [12]Baek G., Choi H., Kim Y., Lee H. C., Choi C., Mesenchymal stem cell-derived extracellular vesicles as therapeutics and as a drug delivery platform. Stem Cells Transl. Med. 8, 880– 886 (2019). 31045328 PMC6708072
  10. [13]Rani S., Ryan A. E., Griffin M. D., Ritter T., Mesenchymal stem cell-derived extracellular vesicles: Toward cell-free therapeutic applications. Mol. Ther. 23, 812– 823 (2015). 25868399 PMC4427881
  11. [14]Panés J., García-Olmo D., Van Assche G., Colombel J. F., Reinisch W., Baumgart D. C., Dignass A., Nachury M., Ferrante M., Kazemi-Shirazi L., Grimaud J. C., de la Portilla F., Goldin E., Richard M. P., Leselbaum A., Danese S., Collaborators A. C. S. G., Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: A phase 3 randomised, double-blind controlled trial. Lancet 388, 1281– 1290 (2016). 27477896
  12. [15]Detela G., Lodge A., EU regulatory pathways for ATMPs: Standard, accelerated and adaptive pathways to marketing authorisation. Mol. Ther. Methods Clin. Dev. 13, 205– 232 (2019). 30815512 PMC6378853
  13. [18]Golchin A., Seyedjafari E., Ardeshirylajimi A., Mesenchymal stem cell therapy for COVID-19: Present or future. Stem Cell Rev. Rep., 427– 433 (2020). 32281052 PMC7152513
  14. [19]Galipeau J., Sensébé L., Mesenchymal stromal cells: Clinical challenges and therapeutic opportunities. Cell Stem Cell 22, 824– 833 (2018). 29859173 PMC6434696
  15. [21]Zhang T. Y., Huang B., Yuan Z. Y., Hu Y. L., Tabata Y., Gao J. Q., Gene recombinant bone marrow mesenchymal stem cells as a tumor-targeted suicide gene delivery vehicle in pulmonary metastasis therapy using non-viral transfection. Nanomedicine 10, 257– 267 (2014). 23770065
  16. [22]Ko I. K., Kean T. J., Dennis J. E., Targeting mesenchymal stem cells to activated endothelial cells. Biomaterials 30, 3702– 3710 (2009). 19375791 PMC2693266
  17. [23]Martinez-Quintanilla J., He D., Wakimoto H., Alemany R., Shah K., Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol. Ther. 23, 108– 118 (2015). 25352242 PMC4426809
  18. [26]De Wolf C., Van De Bovenkamp M., Hoefnagel M., Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy. Cytotherapy 19, 784– 797 (2017). 28457740
  19. [27]Guadix J. A., Lopez-Beas J., Clares B., Soriano-Ruiz J. L., Zugaza J. L., Galvez-Martin P., Principal criteria for evaluating the quality, safety and efficacy of hMSC-based products in clinical practice: Current approaches and challenges. Pharmaceutics 11, 552 (2019). PMC6921040 31652984
  20. [28]Juneja S. C., Viswanathan S., Ganguly M., Veillette C., A simplified method for the aspiration of bone marrow from patients undergoing hip and knee joint replacement for isolating mesenchymal stem cells and in vitro chondrogenesis. Bone Marrow Res. 2016, 3152065 (2016). 27057356 PMC4766320
  21. [29]Yin J. Q., Zhu J., Ankrum J. A., Manufacturing of primed mesenchymal stromal cells for therapy. Nat. Biomed. Eng. 3, 90– 104 (2019). 30944433
  22. [30]Trivedi A., Miyazawa B., Gibb S., Valanoski K., Vivona L., Lin M., Potter D., Stone M., Norris P. J., Murphy J., Smith S., Schreiber M., Pati S., Bone marrow donor selection and characterization of MSCs is critical for pre-clinical and clinical cell dose production. J. Transl. Med. 17, 128 (2019). 30995929 PMC6469059
  23. [31]François M., Romieu-Mourez R., Li M., Galipeau J., Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol. Ther. 20, 187– 195 (2012). 21934657
  24. [33]Zhukareva V., Obrocka M., Houle J. D., Fischer I., Neuhuber B., Secretion profile of human bone marrow stromal cells: Donor variability and response to inflammatory stimuli. Cytokine 50, 317– 321 (2010). 20185331
  25. [34]Russell A. L., Lefavor R., Durand N., Glover L., Zubair A. C., Modifiers of mesenchymal stem cell quantity and quality. Transfusion 58, 1434– 1440 (2018). 29582436
  26. [35]Chinnadurai R., Rajan D., Qayed M., Arafat D., Garcia M., Liu Y., Kugathasan S., Anderson L. J., Gibson G., Galipeau J., Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach. Cell Rep. 22, 2504– 2517 (2018). 29490284 PMC5855117
  27. [36]Salem B., Miner S., Hensel N. F., Battiwalla M., Keyvanfar K., Stroncek D. F., Gee A. P., Hanley P. J., Bollard C. M., Ito S., Barrett A. J., Quantitative activation suppression assay to evaluate human bone marrow–derived mesenchymal stromal cell potency. Cytotherapy 17, 1675– 1686 (2015). 26422657 PMC4655179
  28. [37]Bloom D. D., Centanni J. M., Bhatia N., Emler C. A., Drier D., Leverson G. E., McKenna D. H., Gee A. P., Lindblad R., Hei D. J., Hematti P., A reproducible immunopotency assay to measure mesenchymal stromal cell–mediated T-cell suppression. Cytotherapy 17, 140– 151 (2015). 25455739 PMC4297551
  29. [39]Kuçi Z., Bönig H., Kreyenberg H., Bunos M., Jauch A., Janssen J. W. G., Škifić M., Michel K., Eising B., Lucchini G., Bakhtiar S., Greil J., Lang P., Basu O., von Luettichau I., Schulz A., Sykora K.-W., Jarisch A., Soerensen J., Salzmann-Manrique E., Seifried E., Klingebiel T., Bader P., Kuçi S., Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: A multicenter survey. Haematologica 101, 985– 994 (2016). 27175026 PMC4967578
  30. [40]Galipeau J., The mesenchymal stromal cells dilemma—Does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 15, 2– 8 (2013). 23260081
  31. [41]Rao V. V., Vu M. K., Ma H., Killaars A. R., Anseth K. S., Rescuing mesenchymal stem cell regenerative properties on hydrogel substrates post serial expansion. Bioeng. Transl. Med. 4, 51– 60 (2019). 30680318 PMC6336661
  32. [42]Bunpetch V., Zhang Z. Y., Zhang X., Han S., Zongyou P., Wu H., Hong-Wei O., Strategies for MSC expansion and MSC-based microtissue for bone regeneration. Biomaterials 196, 67– 79 (2019). 29602560
  33. [43]Ho S. S., Murphy K. C., Binder B. Y., Vissers C. B., Leach J. K., Increased survival and function of mesenchymal stem cell spheroids entrapped in instructive alginate hydrogels. Stem Cells Transl. Med. 5, 773– 781 (2016). 27057004 PMC4878334
  34. [44]Ozay E. I., Vijayaraghavan J., Gonzalez-Perez G., Shanthalingam S., Sherman H. L., Garrigan D. T., Chandiran K., Torres J. A., Osborne B. A., Tew G. N., Slukvin I. I., Macdonald R. A., Kelly K., Minter L. M., Cymerus™ iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of Graft-vs-host disease. Stem Cell Res. 35, 101401 (2019). 30738321 PMC6544140
  35. [45]Vodyanik M. A., Yu J., Zhang X., Tian S., Stewart R., Thomson J. A., Slukvin I. I., A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell 7, 718– 729 (2010). 21112566 PMC3033587
  36. [46]Cox G., Boxall S. A., Giannoudis P. V., Buckley C. T., Roshdy T., Churchman S. M., McGonagle D., Jones E., High abundance of CD271+ multipotential stromal cells (MSCs) in intramedullary cavities of long bones. Bone 50, 510– 517 (2012). 21807134 PMC3268250
  37. [47]Lee A. S., Tang C., Rao M. S., Weissman I. L., Wu J. C., Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19, 998 (2013). 23921754 PMC3967018
  38. [49]Hu X., Li L., Yu X., Zhang R., Yan S., Zeng Z., Shu Y., Zhao C., Wu X., Lei J., Li Y., Zhang W., Yang C., Wu K., Wu Y., An L., Huang S., Ji X., Gong C., Yuan C., Zhang L., Liu W., Huang B., Feng Y., Zhang B., Haydon R. C., Luu H. H., Reid R. R., Lee M. J., Wolf J. M., Yu Z., He T.-C., CRISPR/Cas9-mediated reversibly immortalized mouse bone marrow stromal stem cells (BMSCs) retain multipotent features of mesenchymal stem cells (MSCs). Oncotarget 8, 111847– 111865 (2017). 29340096 PMC5762364
  39. [50]Wilson J. G., Liu K. D., Zhuo H., Caballero L., McMillan M., Fang X., Cosgrove K., Vojnik R., Calfee C. S., Lee J. W., Rogers A. J., Levitt J., Wiener-Kronish J., Bajwa E. K., Leavitt A., McKenna D., Thompson B. T., Matthay M. A., Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial. Lancet Respir. Med. 3, 24– 32 (2015). 25529339 PMC4297579
  40. [51]Matthay M. A., Calfee C. S., Zhuo H. J., Thompson B. T., Wilson J. G., Levitt J. E., Rogers A. J., Gotts J. E., Wiener-Kronish J. P., Bajwa E. K., Donahoe M. P., McVerry B. J., Ortiz L. A., Exline M., Christman J. W., Abbott J., Delucchi K. L., Caballero L., McMillan M., McKenna D. H., Liu K. D., Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): A randomised phase 2a safety trial. Lancet Respir. Med. 7, 154– 162 (2019). 30455077 PMC7597675
  41. [52]Francois M., Copland I. B., Yuan S., Romieu-Mourez R., Waller E. K., Galipeau J., Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 14, 147– 152 (2012). 22029655 PMC3279133
  42. [54]Moll G., Alm J. J., Davies L. C., von Bahr L., Heldring N., Stenbeck-Funke L., Hamad O. A., Hinsch R., Ignatowicz L., Locke M., Lonnies H., Lambris J. D., Teramura Y., Nilsson-Ekdahl K., Nilsson B., Le Blanc K., Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells 32, 2430– 2442 (2014). 24805247 PMC4381870
  43. [55]Lalu M. M., McIntyre L., Pugliese C., Fergusson D., Winston B. W., Marshall J. C., Granton J., Stewart D. J., Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PLOS ONE 7, e47559 (2012). 23133515 PMC3485008
  44. [56]Bader P., Kuci Z., Bakhtiar S., Basu O., Bug G., Dennis M., Greil J., Barta A., Kallay K. M., Lang P., Lucchini G., Pol R., Schulz A., Sykora K. W., von Luettichau I., Herter-Sprie G., Uddin M. A., Jenkin P., Alsultan A., Buechner J., Stein J., Kelemen A., Jarisch A., Soerensen J., Salzmann-Manrique E., Hutter M., Schafer R., Seifried E., Klingebiel T., Bonig H., Kuci S., Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transplant. 53, 852– 862 (2018). 29379171 PMC6039391
  45. [57]Gothelf Y., Abramov N., Harel A., Offen D., Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells. Clin. Transl. Med. 3, 21 (2014). 25097724 PMC4108239
  46. [58]Wang Y., Chen X., Cao W., Shi Y., Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications. Nat. Immunol. 15, 1009 (2014). 25329189
  47. [59]Gothelf Y., Kaspi H., Abramov N., Aricha R., miRNA profiling of NurOwn (R): Mesenchymal stem cells secreting neurotrophic factors. Stem Cell. Res. Ther. 8, (2017). PMC5678806 29116031
  48. [60]Ranganath S. H., Tong Z., Levy O., Martyn K., Karp J. M., Inamdar M. S., Controlled inhibition of the mesenchymal stromal cell pro-inflammatory secretome via microparticle engineering. Stem Cell Rep. 6, 926– 939 (2016). PMC4911501 27264972
  49. [61]Levy O., Brennen W. N., Han E., Rosen D. M., Musabeyezu J., Safaee H., Ranganath S., Ngai J., Heinelt M., Milton Y., Wang H., Bhagchandani S. H., Joshi N., Bhowmick N., Denmeade S. R., Isaacs J. T., Karp J. M., A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials 91, 140– 150 (2016). 27019026 PMC4824400
  50. [62]Ankrum J. A., Miranda O. R., Ng K. S., Sarkar D., Xu C., Karp J. M., Engineering cells with intracellular agent-loaded microparticles to control cell phenotype. Nat. Protoc. 9, 233– 245 (2014). 24407352 PMC4320648
  51. [63]Ankrum J. A., Dastidar R. G., Ong J. F., Levy O., Karp J. M., Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids. Sci. Rep. 4, 4645 (2014). 24717973 PMC3982175
  52. [64]Suresh S. C., Selvaraju V., Thirunavukkarasu M., Goldman J. W., Husain A., Alexander Palesty J., Sanchez J. A., McFadden D. W., Maulik N., Thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy increased pro-angiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium. Int. J. Cardiol. 201, 517– 528 (2015). 26322599
  53. [65]Chabner B. A., Roberts T. G., Timeline—Chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65– 72 (2005). 15630416
  54. [66]Thanuja M. Y., Anupama C., Ranganath S. H., Bioengineered cellular and cell membrane-derived vehicles for actively targeted drug delivery: So near and yet so far. Adv. Drug Del. Rev. 132, 57– 80 (2018). 29935987
  55. [67]Sasportas L. S., Kasmieh R., Wakimoto H., Hingtgen S., van de Water J. A., Mohapatra G., Figueiredo J. L., Martuza R. L., Weissleder R., Shah K., Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 106, 4822– 4827 (2009). 19264968 PMC2660771
  56. [68]Matuskova M., Baranovicova L., Kozovska Z., Durinikova E., Pastorakova A., Hunakova L., Waczulikova I., Nencka R., Kucerova L., Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells. J. Gene Med. 14, 776– 787 (2012). 23150190
  57. [69]Niess H., Bao Q., Conrad C., Zischek C., Notohamiprodjo M., Schwab F., Schwarz B., Huss R., Jauch K. W., Nelson P. J., Bruns C. J., Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann. Surg. 254, 767– 774 (2011). 22042469
  58. [70]Liu L., Zhang S. X., Liao W., Farhoodi H. P., Wong C. W., Chen C. C., Segaliny A. I., Chacko J. V., Nguyen L. P., Lu M., Polovin G., Pone E. J., Downing T. L., Lawson D. A., Digman M. A., Zhao W., Mechanoresponsive stem cells to target cancer metastases through biophysical cues. Sci. Transl. Med. 9, (2017). PMC5890431 28747514
  59. [71]Gujar S., Pol J. G., Kim Y., Lee P. W., Kroemer G., Antitumor benefits of antiviral immunity: An underappreciated aspect of oncolytic virotherapies. Trends Immunol. 39, 209– 221 (2018). 29275092
  60. [72]Wakimoto H., Ikeda K., Abe T., Ichikawa T., Hochberg F. H., Ezekowitz R. A. B., Pasternack M. S., Chiocca E. A., The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. 5, 275– 282 (2002). 11863417
  61. [73]Ikeda K., Ichikawa T., Wakimoto H., Silver J. S., Deisboeck T. S., Finkelstein D., Harsh IV G. R., Louis D. N., Bartus R. T., Hochberg F. H., Chiocca E. A., Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5, 881– 887 (1999). 10426310
  62. [74]Power A. T., Wang J., Falls T. J., Paterson J. M., Parato K. A., Lichty B. D., Stojdl D. F., Forsyth P. A. J., Atkins H., Bell J. C., Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. 15, 123– 130 (2007). 17164783
  63. [75]Conget P. A., Minguell J. J., Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp. Hematol. 28, 382– 390 (2000). 10781896
  64. [76]Hammer K., Kazcorowski A., Liu L., Behr M., Schemmer P., Herr I., Nettelbeck D. M., Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells. Int. J. Cancer 137, 978– 990 (2015). 25604186
  65. [78]Niess H., von Einem J. C., Thomas M. N., Michl M., Angele M. K., Huss R., Gunther C., Nelson P. J., Bruns C. J., Heinemann V., Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): Study protocol of a phase I/II clinical trial. BMC Cancer 15, 237 (2015). 25879229 PMC4393860
  66. [79]Wei W., Huang Y., Li D., Gou H. F., Wang W., Improved therapeutic potential of MSCs by genetic modification. Gene Ther. 25, 538– 547 (2018). 30254305
  67. [80]Thakkar U. G., Trivedi H. L., Vanikar A. V., Dave S. D., Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy 17, 940– 947 (2015). 25869301
  68. [81]Antunes M. A., Abreu S. C., Cruz F. F., Teixeira A. C., Lopes-Pacheco M., Bandeira E., Olsen P. C., Diaz B. L., Takyia C. M., Freitas I., Rocha N. N., Capelozzi V. L., Xisto D. G., Weiss D. J., Morales M. M., Rocco P. R. M., Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema. Respir. Res. 15, (2014). PMC4189723 25272959
  69. [82]de Witte S. F. H., Luk F., Sierra Parraga J. M., Gargesha M., Merino A., Korevaar S. S., Shankar A. S., O’Flynn L., Elliman S. J., Roy D., Betjes M. G. H., Newsome P. N., Baan C. C., Hoogduijn M. J., Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells 36, 602– 610 (2018). 29341339
  70. [83]Eggenhofer E., Benseler V., Kroemer A., Popp F., Geissler E., Schlitt H., Baan C., Dahlke M., Hoogduijn M., Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front. Immunol. 3, 297 (2012). 23056000 PMC3458305
  71. [84]O’Cearbhaill E. D., Ng K. S., Karp J. M., Emerging medical devices for minimally invasive cell therapy. Mayo Clin. Proc. 89, 259– 273 (2014). 24485137
  72. [87]Kanelidis A. J., Premer C., Lopez J., Balkan W., Hare J. M., Route of delivery modulates the efficacy of mesenchymal stem cell therapy for myocardial infarction a meta-analysis of preclinical studies and clinical trials. Circ. Res. 120, 1139 (2017). 28031416 PMC5656247
  73. [88]Ullah M., Liu D. D., Thakor A. S., Mesenchymal stromal cell homing: Mechanisms and strategies for improvement. Science 15, 421– 438 (2019). PMC6529790 31121468
  74. [89]Madl C. M., Heilshorn S. C., Blau H. M., Bioengineering strategies to accelerate stem cell therapeutics. Nature 557, 335– 342 (2018). 29769665 PMC6773426
  75. [90]Li L., Chen X., Wang W. E., Zeng C., How to improve the survival of transplanted mesenchymal stem cell in ischemic heart? Stem Cells Int. 2016, 9682757 (2016). 26681958 PMC4670674
  76. [91]Burdick J. A., Mauck R. L., Gerecht S., To serve and protect: Hydrogels to improve stem cell-based therapies. Cell Stem Cell 18, 13– 15 (2016). 26748751
  77. [92]Hofmann M., Wollert K. C., Meyer G. P., Menke A., Arseniev L., Hertenstein B., Ganser A., Knapp W. H., Drexler H., Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111, 2198– 2202 (2005). 15851598
  78. [94]Wu Z., Chen G., Zhang J., Hua Y., Li J., Liu B., Huang A., Li H., Chen M., Ou C., Treatment of myocardial infarction with gene-modified mesenchymal stem cells in a small molecular hydrogel. Sci. Rep. 7, 15826 (2017). 29158523 PMC5696474
  79. [95]Muschler G. F., Nakamoto C., Griffith L. G., Engineering principles of clinical cell-based tissue engineering. J. Bone Joint Surg. Am. 86, 1541– 1558 (2004). 15252108
  80. [96]Gleeson B. M., Martin K., Ali M. T., Kumar A. H. S., Pillai M. G.-K., Kumar S. P. G., O’Sullivan J. F., Whelan D., Stocca A., Khider W., Barry F. P., O’Brien T., Caplice N. M., Bone marrow-derived mesenchymal stem cells have innate procoagulant activity and cause microvascular obstruction following intracoronary delivery: Amelioration by antithrombin therapy. Stem Cells 33, 2726– 2737 (2015). 25969127
  81. [97]Toma C., Wagner W. R., Bowry S., Schwartz A., Villanueva F., Fate of culture-expanded mesenchymal stem cells in the microvasculature: In vivo observations of cell kinetics. Circ. Res. 104, 398– 402 (2009). 19096027 PMC3700384
  82. [98]Wu Z., Zhang S., Zhou L., Cai J., Tan J., Gao X., Zeng Z., Li D., Thromboembolism induced by umbilical cord mesenchymal stem cell infusion: A report of two cases and literature review. Transplant. Proc. 49, 1656– 1658 (2017). 28838459
  83. [99]Moll G., Ignatowicz L., Catar R., Luecht C., Sadeghi B., Hamad O., Jungebluth P., Dragun D., Schmidtchen A., Ringden O., Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua. Stem Cells Dev. 24, 2269– 2279 (2015). 26192403
  84. [100]Oeller M., Laner-Plamberger S., Hochmann S., Ketterl N., Feichtner M., Brachtl G., Hochreiter A., Scharler C., Bieler L., Romanelli P., Couillard-Despres S., Russe E., Schallmoser K., Strunk D., Selection of tissue factor-deficient cell transplants as a novel strategy for improving hemocompatibility of human bone marrow stromal cells. Theranostics 8, 1421– 1434 (2018). 29507631 PMC5835947
  85. [101]Christy B. A., Herzig M. C., Montgomery R. K., Delavan C., Bynum J. A., Reddoch K. M., Cap A. P., Procoagulant activity of human mesenchymal stem cells. J. Trauma Acute Care Surg. 83, S164– S169 (2017). 28628602
  86. [102]George M. J., Prabhakara K., Toledano-Furman N. E., Wang Y. W., Gill B. S., Wade C. E., Olson S. D., Cox C. S. Jr., Clinical cellular therapeutics accelerate clot formation. Stem Cells Transl. Med. 7, 731– 739 (2018). 30070065 PMC6186273
  87. [103]Li Y., Lin F., Mesenchymal stem cells are injured by complement after their contact with serum. Blood 120, 3436– 3443 (2012). 22966167 PMC3482856
  88. [104]Markiewski M. M., Nilsson B., Ekdahl K. N., Mollnes T. E., Lambris J. D., Complement and coagulation: Strangers or partners in crime? Trends Immunol. 28, 184– 192 (2007). 17336159
  89. [105]Kraitchman D. L., Tatsumi M., Gilson W. D., Ishimori T., Kedziorek D., Walczak P., Segars W. P., Chen H. H., Fritzges D., Izbudak I., Young R. G., Marcelino M., Pittenger M. F., Solaiyappan M., Boston R. C., Tsui B. M., Wahl R. L., Bulte J. W., Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 112, 1451– 1461 (2005). 16129797 PMC1456731
  90. [106]Wagner B., Henschler R., Fate of intravenously injected mesenchymal stem cells and significance for clinical application. Adv. Biochem. Eng. Biotechnol. 130, 19– 37 (2013). 23334265
  91. [107]Scarfe L., Taylor A., Sharkey J., Harwood R., Barrow M., Comenge J., Beeken L., Astley C., Santeramo I., Hutchinson C., Ressel L., Smythe J., Austin E., Levy R., Rosseinsky M. J., Adams D. J., Poptani H., Park B. K., Murray P., Wilm B., Non-invasive imaging reveals conditions that impact distribution and persistence of cells after in vivo administration. Stem Cell. Res. Ther. 9, 332 (2018). 30486897 PMC6264053
  92. [108]Mao A. S., Ozkale B., Shah N. J., Vining K. H., Descombes T., Zhang L., Tringides C. M., Wong S. W., Shin J. W., Scadden D. T., Weitz D. A., Mooney D. J., Programmable microencapsulation for enhanced mesenchymal stem cell persistence and immunomodulation. Proc. Natl. Acad. Sci. U.S.A. 116, 15392– 15397 (2019). 31311862 PMC6681761
  93. [109]Kang W. J., Kang H. J., Kim H. S., Chung J. K., Lee M. C., Lee D. S., Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J. Nucl. Med. 47, 1295– 1301 (2006). 16883008
  94. [110]Schweizer M. T., Wang H., Bivalacqua T. J., Partin A. W., Lim S. J., Chapman C., Abdallah R., Levy O., Bhowmick N. A., Karp J. M., De Marzo A., Isaacs J. T., Brennen W. N., Denmeade S. R., A phase i study to assess the safety and cancer-homing ability of allogeneic bone marrow-derived mesenchymal stem cells in men with localized prostate cancer. Stem Cells Transl. Med. 8, 441– 449 (2019). 30735000 PMC6477003
  95. [111]Hu X., Yu S. P., Fraser J. L., Lu Z., Ogle M. E., Wang J. A., Wei L., Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J. Thorac. Cardiovasc. Surg. 135, 799– 808 (2008). 18374759
  96. [112]Levit R. D., Landazuri N., Phelps E. A., Brown M. E., Garcia A. J., Davis M. E., Joseph G., Long R., Safley S. A., Suever J. D., Lyle A. N., Weber C. J., Taylor W. R., Cellular encapsulation enhances cardiac repair. J. Am. Heart Assoc. 2, e000367 (2013). 24113327 PMC3835246
  97. [113]Zanotti L., Sarukhan A., Dander E., Castor M., Cibella J., Soldani C., Trovato A. E., Ploia C., Luca G., Calvitti M., Mancuso F., Arato I., Golemac M., Jonjic N., Biondi A., Calafiore R., Locati M., D’Amico G., Viola A., Encapsulated mesenchymal stem cells for in vivo immunomodulation. Leukemia 27, 500– 503 (2013). 22878604
  98. [114]Kim I., Lee S. K., Yoon J. I., Kim D. E., Kim M., Ha H., Fibrin glue improves the therapeutic effect of MSCs by sustaining survival and paracrine function. Tissue Eng. Part A 19, 2373– 2381 (2013). 23701237 PMC3807701
  99. [115]Caldwell A. S., Rao V. V., Golden A. C., Anseth K. S., Porous bio-click microgel scaffolds control hMSC interactions and promote their secretory properties. Biomaterials 232, 119725 (2020). 31918222 PMC7047645
  100. [116]Cai L., Dewi R. E., Goldstone A. B., Cohen J. E., Steele A. N., Woo Y. J., Heilshorn S. C., Regulating stem cell secretome using injectable hydrogels with in situ network formation. Adv. Healthc. Mater. 5, 2758– 2764 (2016). 27709809 PMC5521188
  101. [117]Qazi T. H., Tytgat L., Dubruel P., Duda G. N., Vlierberghe S. V., Geissler S., Extrusion printed scaffolds with varying pore size as modulators of MSC angiogenic paracrine effects. ACS Biomater Sci. Eng. 5, 5348– 5358 (2019). 33464076
  102. [118]Clark A. Y., Martin K. E., Garcia J. R., Johnson C. T., Theriault H. S., Han W. M., Zhou D. W., Botchwey E. A., Garcia A. J., Integrin-specific hydrogels modulate transplanted human bone marrow-derived mesenchymal stem cell survival, engraftment, and reparative activities. Nat. Commun. 11, 114 (2020). 31913286 PMC6949269
  103. [119]García J. R., Quiros M., Han W. M., O’Leary M. N., Cox G. N., Nusrat A., García A. J., IFN-gamma-tethered hydrogels enhance mesenchymal stem cell-based immunomodulation and promote tissue repair. Biomaterials 220, 119403 (2019). 31401468 PMC6717550
  104. [120]Moll G., Hult A., von Bahr L., Alm J. J., Heldring N., Hamad O. A., Stenbeck-Funke L., Larsson S., Teramura Y., Roelofs H., Nilsson B., Fibbe W. E., Olsson M. L., Le Blanc K., Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells? PLOS ONE 9, e85040 (2014). 24454787 PMC3890285
  105. [121]Baygan A., Aronsson-Kurttila W., Moretti G., Tibert B., Dahllof G., Klingspor L., Gustafsson B., Khoein B., Moll G., Hausmann C., Svahn B. M., Westgren M., Remberger M., Sadeghi B., Ringden O., Safety and side effects of using placenta-derived decidual stromal cells for graft-versus-host disease and hemorrhagic cystitis. Front. Immunol. 8, 795 (2017). 28744284 PMC5504152
  106. [122]Ringden O., Baygan A., Remberger M., Gustafsson B., Winiarski J., Khoein B., Moll G., Klingspor L., Westgren M., Sadeghi B., Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease. Stem Cells Transl. Med. 7, 325– 331 (2018). 29533533 PMC5866941
  107. [123]Nilsson B., Korsgren O., Lambris J. D., Ekdahl K. N., Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol. 31, 32– 38 (2010). 19836998 PMC2818156
  108. [124]Soland M. A., Bego M., Colletti E., Zanjani E. D., Jeor S. S., Porada C. D., Almeida-Porada G., Mesenchymal stem cells engineered to inhibit complement-mediated damage. PLOS ONE 8, e60461 (2013). 23555976 PMC3608620
  109. [125]Kamperman T., Karperien M., Le Gac S., Leijten J., Single-cell microgels: Technology, challenges, and applications. Trends Biotechnol. 36, 850– 865 (2018). 29656795
  110. [126]Shi M., Li J., Liao L., Chen B., Li B., Chen L., Jia H., Zhao R. C., Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: Role in homing efficiency in NOD/SCID mice. Haematologica 92, 897– 904 (2007). 17606439
  111. [127]Tsai L. K., Leng Y., Wang Z., Leeds P., Chuang D. M., The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology 35, 2225– 2237 (2010). 20613717 PMC3055307
  112. [128]Tsai L.-K., Wang Z., Munasinghe J., Leng Y., Leeds P., Chuang D. M., Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke 42, 2932– 2939 (2011). 21836090 PMC3183311
  113. [129]Yu Q., Chen L., You Y., Zou C., Zhang Y., Liu Q., Cheng F., Erythropoietin combined with granulocyte colonystimulating factor enhances MMP-2 expression in mesenchymal stem cells and promotes cell migration. Mol. Med. Report. 4, 31– 36 (2011). 21461559
  114. [130]Kim Y. S., Noh M. Y., Kim J. Y., Yu H. J., Kim K. S., Kim S. H., Koh S. H., Direct GSK-3beta inhibition enhances mesenchymal stromal cell migration by increasing expression of beta-PIX and CXCR4. Mol. Neurobiol. 47, 811– 820 (2013). 23288365
  115. [131]Levy O., Zhao W., Mortensen L. J., Leblanc S., Tsang K., Fu M., Phillips J. A., Sagar V., Anandakumaran P., Ngai J., Cui C. H., Eimon P., Angel M., Lin C. P., Yanik M. F., Karp J. M., mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 122, e23– e32 (2013). 23980067 PMC3790516
  116. [132]Liao W., Pham V., Liu L., Riazifar M., Pone E. J., Zhang S. X., Ma F., Lu M., Walsh C. M., Zhao W., Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis. Biomaterials 77, 87– 97 (2016). 26584349 PMC4684451
  117. [133]Cheng Z., Ou L., Zhou X., Li F., Jia X., Zhang Y., Liu X., Li Y., Ward C. A., Melo L. G., Kong D., Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol. Ther. 16, 571– 579 (2008). 18253156
  118. [134]Zhang D., Fan G. C., Zhou X., Zhao T., Pasha Z., Xu M., Zhu Y., Ashraf M., Wang Y., Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J. Mol. Cell. Cardiol. 44, 281– 292 (2008). 18201717 PMC2601571
  119. [135]Bobis-Wozowicz S., Miekus K., Wybieralska E., Jarocha D., Zawisz A., Madeja Z., Majka M., Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice. Exp. Hematol. 39, 686– 696.e4 (2011). 21426925
  120. [136]Chen W., Li M., Cheng H., Yan Z., Cao J., Pan B., Sang W., Wu Q., Zeng L., Li Z., Xu K., Overexpression of the mesenchymal stem cell Cxcr4 gene in irradiated mice increases the homing capacity of these cells. Cell Biochem. Biophys. 67, 1181– 1191 (2013). 23712865
  121. [137]Chen Z., Chen Q., Du H., Xu L., Wan J., Mesenchymal stem cells and CXC chemokine receptor 4 overexpression improved the therapeutic effect on colitis via mucosa repair. Exp. Ther. Med. 16, 821– 829 (2018). 30112037 PMC6090451
  122. [138]Corradetti B., Taraballi F., Martinez J. O., Minardi S., Basu N., Bauza G., Evangelopoulos M., Powell S., Corbo C., Tasciotti E., Hyaluronic acid coatings as a simple and efficient approach to improve MSC homing toward the site of inflammation. Sci. Rep. 7, 7991 (2017). 28801676 PMC5554184
  123. [139]Sackstein R., Merzaban J. S., Cain D. W., Dagia N. M., Spencer J. A., Lin C. P., Wohlgemuth R., Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat. Med. 14, 181– 187 (2008). 18193058
  124. [140]Abdi R., Moore R., Sakai S., Donnelly C. B., Mounayar M., Sackstein R., HCELL expression on murine msc licenses pancreatotropism and confers durable reversal of autoimmune diabetes in NOD mice. Stem Cells 33, 1523– 1531 (2015). 25641589 PMC4447299
  125. [141]Sarkar D., Vemula P. K., Teo G. S., Spelke D., Karnik R., Weele Y., Karp J. M., Chemical engineering of mesenchymal stem cells to induce a cell rolling response. Bioconjug. Chem. 19, 2105– 2109 (2008). 18973352
  126. [142]Cheng H., Byrska-Bishop M., Zhang C. T., Kastrup C. J., Hwang N. S., Tai A. K., Lee W. W., Xu X., Nahrendorf M., Langer R., Anderson D. G., Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell-selectin interaction kinetics. Biomaterials 33, 5004– 5012 (2012). 22494889 PMC3366278
  127. [143]Xiao W., Green T. I. P., Liang X., Delint R. C., Perry G., Roberts M. S., Le Vay K., Back C. R., Ascione R., Wang H., Race P. R., Perriman A. W., Designer artificial membrane binding proteins to direct stem cells to the myocardium. Chem. Sci. 10, 7610– 7618 (2019). 31588312 PMC6764276
  128. [144]Lo C. Y., Antonopoulos A., Dell A., Haslam S. M., Lee T., Neelamegham S., The use of surface immobilization of P-selectin glycoprotein ligand-1 on mesenchymal stem cells to facilitate selectin mediated cell tethering and rolling. Biomaterials 34, 8213– 8222 (2013). 23891082 PMC3943335
  129. [145]Arbab A. S., Jordan E. K., Wilson L. B., Yocum G. T., Lewis B. K., Frank J. A., In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum. Gene Ther. 15, 351– 360 (2004). 15053860
  130. [146]Song Y. S., Ku J. H., Monitoring transplanted human mesenchymal stem cells in rat and rabbit bladders using molecular magnetic resonance imaging. Neurourol.Urodyn. 26, 584– 593 (2007). 17357122
  131. [147]Yanai A., Hafeli U. O., Metcalfe A. L., Soema P., Addo L., Gregory-Evans C. Y., Po K., Shan X., Moritz O. L., Gregory-Evans K., Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles. Cell Transplant. 21, 1137– 1148 (2012). 22405427
  132. [148]Hsiao J. K., Tai M. F., Chu H. H., Chen S. T., Li H., Lai D. M., Hsieh S. T., Wang J. L., Liu H. M., Magnetic nanoparticle labeling of mesenchymal stem cells without transfection agent: Cellular behavior and capability of detection with clinical 1.5 T magnetic resonance at the single cell level. Magn. Reson. Med. 58, 717– 724 (2007). 17899592
  133. [149]Wang S., Lu B., Girman S., Duan J., McFarland T., Zhang Q.-s., Grompe M., Adamus G., Appukuttan B., Lund R., Non-invasive stem cell therapy in a rat model for retinal degeneration and vascular pathology. PLOS ONE 5, e9200 (2010). 20169166 PMC2821411
  134. [150]Vagnozzi R. J., Maillet M., Sargent M. A., Khalil H., Johansen A. K. Z., Schwanekamp J. A., York A. J., Huang V., Nahrendorf M., Sadayappan S., Molkentin J. D., An acute immune response underlies the benefit of cardiac stem cell therapy. Nature 577, 405– 409 (2020). 31775156 PMC6962570
  135. [151]Hess D. C., Wechsler L. R., Clark W. M., Savitz S. I., Ford G. A., Chiu D., Yavagal D. R., Uchino K., Liebeskind D. S., Auchus A. P., Sen S., Sila C. A., Vest J. D., Mays R. W., Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 16, 360– 368 (2017). 28320635
  136. [152]Noronha N. C., Mizukami A., Caliari-Oliveira C., Cominal J. G., Rocha J. L. M., Covas D. T., Swiech K., Malmegrim K. C. R., Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell. Res. Ther. 10, 131 (2019). 31046833 PMC6498654
  137. [153]Yang J., Chen X., Yuan T., Yang X., Fan Y., Zhang X., Regulation of the secretion of immunoregulatory factors of mesenchymal stem cells (MSCs) by collagen-based scaffolds during chondrogenesis. Korean J. Couns. Psychother. 70, 983– 991 (2017). 27772730
  138. [154]Herrera J., Henke C. A., Bitterman P. B., Extracellular matrix as a driver of progressive fibrosis. J. Clin. Invest. 128, 45– 53 (2018). 29293088 PMC5749528
  139. [155]Tisato V., Naresh K., Girdlestone J., Navarrete C., Dazzi F., Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 21, 1992– 1999 (2007). 17625609
  140. [156]Kyriakou C., Rabin N., Pizzey A., Nathwani A., Yong K., Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model. Haematologica 93, 1457– 1465 (2008). 18728032
  141. [157]Salem N., Salem M. Y., Elmaghrabi M. M., Elawady M. A., Elawady M. A., Sabry D., Shamaa A., Elkasapy A. H., Ibrhim N., Elamir A., Does vitamin C have the ability to augment the therapeutic effect of bone marrow-derived mesenchymal stem cells on spinal cord injury? Neural Regen. Res. 12, 2050– 2058 (2017). 29323045 PMC5784354
  142. [158]Gao J., Dennis J. E., Muzic R. F., Lundberg M., Caplan A. I., The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169, 12– 20 (2001). 11340257
  143. [159]Szabo E., Fajka-Boja R., Kriston-Pal E., Hornung A., Makra I., Kudlik G., Uher F., Katona R. L., Monostori E., Czibula A., Licensing by inflammatory cytokines abolishes heterogeneity of immunosuppressive function of mesenchymal stem cell population. Stem Cells Dev. 24, 2171– 2180 (2015). 26153898
  144. [160]Nakajima M., Nito C., Sowa K., Suda S., Nishiyama Y., Nakamura-Takahashi A., Nitahara-Kasahara Y., Imagawa K., Hirato T., Ueda M., Kimura K., Okada T., Mesenchymal stem cells overexpressing interleukin-10 promote neuroprotection in experimental acute ischemic stroke. Mol. Ther. Methods Clin. Dev. 6, 102– 111 (2017). 28725658 PMC5502709
  145. [161]Guo H., Li B., Wang W., Zhao N., Gao H., Mesenchymal stem cells overexpressing IL-35: A novel immunosuppressive strategy and therapeutic target for inducing transplant tolerance. Stem Cell. Res. Ther. 9, 254 (2018). 30257721 PMC6158805
  146. [162]Huang Y., Li Q., Zhang K., Hu M., Wang Y., Du L., Lin L., Li S., Sorokin L., Melino G., Shi Y., Wang Y., Single cell transcriptomic analysis of human mesenchymal stem cells reveals limited heterogeneity. Cell Death Dis. 10, 368 (2019). 31068579 PMC6506509
  147. [163]Hoban D. B., Howard L., Dowd E., GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson’s disease. Neuroscience 303, 402– 411 (2015). 26166730
  148. [164]Deng P., Torrest A., Pollock K., Dahlenburg H., Annett G., Nolta J. A., Fink K. D., Clinical trial perspective for adult and juvenile Huntington’s disease using genetically-engineered mesenchymal stem cells. Neural Regen. Res. 11, 702– 705 (2016). 27335539 PMC4904446
  149. [165]Pollock K., Dahlenburg H., Nelson H., Fink K. D., Cary W., Hendrix K., Annett G., Torrest A., Deng P., Gutierrez J., Nacey C., Pepper K., Kalomoiris S., McGee D. A. J. J., Gruenloh W., Fury B., Bauer G., Duffy A., Tempkin T., Wheelock V., Nolta J. A., Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington’s disease mouse models. Mol. Ther. 24, 965– 977 (2016). 26765769 PMC4881765
  150. [166]Liu X. S., Li J. F., Wang S. S., Wang Y. T., Zhang Y. Z., Yin H. L., Geng S., Gong H. C., Han B., Wang Y. L., Human umbilical cord mesenchymal stem cells infected with adenovirus expressing HGF promote regeneration of damaged neuron cells in a Parkinson’s disease model. Biomed. Res. Int. 2014, 909657 (2014). 25276829 PMC4167956
  151. [167]Marin-Banasco C., Benabdellah K., Melero-Jerez C., Oliver B., Pinto-Medel M. J., Hurtado-Guerrero I., de Castro F., Clemente D., Fernandez O., Martin F., Leyva L., Suardiaz M., Gene therapy with mesenchymal stem cells expressing IFN-ss ameliorates neuroinflammation in experimental models of multiple sclerosis. Br. J. Pharmacol. 174, 238– 253 (2017). 27882538 PMC5241389
  152. [168]Pelled G., Sheyn D., Tawackoli W., Jun D. S., Koh Y., Su S., Cohn Yakubovich D., Kallai I., Antebi B., Da X., Gazit Z., Bae H., Gazit D., BMP6-engineered MSCs induce vertebral bone repair in a pig model: A pilot study. Stem Cells Int. 2016, 6530624 (2016). 26770211 PMC4685143
  153. [169]Chen G., Zhang Y., Yu S., Sun W., Miao D., Bmi1 overexpression in mesenchymal stem cells exerts anti-aging and anti-osteoporosis effects by inactivating p16/p19 signaling and inhibiting oxidative stress. Stem Cells 0, 1– 12 (2019). PMC6851636 30895687
  154. [170]Jang Y. O., Cho M. Y., Yun C. O., Baik S. K., Park K. S., Cha S. K., Chang S. J., Kim M. Y., Lim Y. L., Kwon S. O., Effect of function-enhanced mesenchymal stem cells infected with decorin-expressing adenovirus on hepatic fibrosis. Stem Cells Transl. Med. 5, 1247– 1256 (2016). 27365486 PMC4996441
  155. [171]Conrad C., Husemann Y., Niess H., von Luettichau I., Huss R., Bauer C., Jauch K. W., Klein C. A., Bruns C., Nelson P. J., Linking transgene expression of engineered mesenchymal stem cells and angiopoietin-1-induced differentiation to target cancer angiogenesis. Ann. Surg. 253, 566– 571 (2011). 21169810
  156. [172]Shah K., Encapsulated stem cells for cancer therapy. Biomatter 3, e24278 (2013). 23507920 PMC3732324
  157. [173]Hu M., Yang J. L., Teng H., Jia Y. Q., Wang R., Zhang X. W., Wu Y., Luo Y., Chen X. C., Zhang R., Tian L., Zhao X., Wei Y. Q., Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model. BMC Cancer 8, 306 (2008). 18947384 PMC2580769
  158. [174]Choi S. H., Tamura K., Khajuria R. K., Bhere D., Nesterenko I., Lawler J., Shah K., Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas. Mol. Ther. 23, 235– 243 (2015). 25358253 PMC4445617
  159. [175]Duebgen M., Martinez-Quintanilla J., Tamura K., Hingtgen S., Redjal N., Wakimoto H., Shah K., Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J. Natl. Cancer Inst. 106, dju090 (2014). 24838834
  160. [176]Alfano A. L., Nicola Candia A., Cuneo N., Guttlein L. N., Soderini A., Rotondaro C., Sganga L., Podhajcer O. L., Lopez M. V., Oncolytic adenovirus-loaded menstrual blood stem cells overcome the blockade of viral activity exerted by ovarian cancer ascites. Mol. Ther. Oncolytics 6, 31– 44 (2017). 28736743 PMC5510493
  161. [177]Moreno R., Rojas L. A., Villellas F. V., Soriano V. C., Garcia-Castro J., Fajardo C. A., Alemany R., Human menstrual blood-derived mesenchymal stem cells as potential cell carriers for oncolytic adenovirus. Stem Cells Int. 2017, 3615729 (2017). 28781596 PMC5525077

Cited by

Sorted by citations

Authors
Levy, O., Kuai, R., Siren, E. M. J., Bhere, D., Milton, Y., Nissar, N., De Biasio, M., Heinelt, M., Reeve, B., Abdi, R., Alturki, M., Fallatah, M., Almalik, A., Alhasan, A. H., Shah, K., & Karp, J. M.
Affiliations
  • Brigham and Women's Hospital (US)
  • Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA.
  • Harvard University (US)
  • King Abdulaziz City for Science and Technology (SA)
  • Broad Institute (US)
Corresponding author
  • Shah, Khalid
  • Karp, Jeffrey M.
ORCID
Venue
Science Advances
Publisher
American Association for the Advancement of Science (AAAS)
Published
2020-07-24
Volume
6
Issue
30
Pages
eaba6884-eaba6884
ISSN
2375-2548 (ISSN-L)
DOI
10.1126/sciadv.aba6884
PMC
PMC7439491
OpenAlex
W3044491460
Cited by
694
References
7
Citations by year
2026: 87 · 2025: 115 · 2024: 126 · 2023: 121 · 2022: 126 · 2021: 110 · 2020: 9
FWCI
13.85
Type
journal article
Language
en
Open access
Licence
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (HL095722, NS107857)
  • King Abdulaziz City for Science and Technology
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Urology › Periodontal Regeneration and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
mesenchymal stem cells, clinical trial efficacy, cellular heterogeneity
MeSH terms
Betacoronavirus, COVID-19, SARS-CoV-2, Graft vs Host Disease, Humans, Pneumonia, Viral, Coronavirus Infections, Bioreactors, Mesenchymal Stem Cell Transplantation, Pandemics, Mesenchymal Stem Cells, Metabolic Engineering, Batch Cell Culture Techniques, Transplant Recipients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review